ATE337001T1 - Antitumorverbindung und ihre therapeutischen verwendungen - Google Patents

Antitumorverbindung und ihre therapeutischen verwendungen

Info

Publication number
ATE337001T1
ATE337001T1 AT03765081T AT03765081T ATE337001T1 AT E337001 T1 ATE337001 T1 AT E337001T1 AT 03765081 T AT03765081 T AT 03765081T AT 03765081 T AT03765081 T AT 03765081T AT E337001 T1 ATE337001 T1 AT E337001T1
Authority
AT
Austria
Prior art keywords
therapeutic uses
antitumor compound
fgf
men2
arylidene
Prior art date
Application number
AT03765081T
Other languages
English (en)
Inventor
Cinzia Lanzi
Giuliana Cassinelli
Giuditta Cuccuru
Marco Alessandro Pierotti
Franco Zunino
Ernesto Menta
Original Assignee
Cell Therapeutics Europe Srl
Ist Naz Stud Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Europe Srl, Ist Naz Stud Cura Dei Tumori filed Critical Cell Therapeutics Europe Srl
Application granted granted Critical
Publication of ATE337001T1 publication Critical patent/ATE337001T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03765081T 2002-07-23 2003-07-22 Antitumorverbindung und ihre therapeutischen verwendungen ATE337001T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002MI001620A ITMI20021620A1 (it) 2002-07-23 2002-07-23 Composto ad ativita' antitumorale

Publications (1)

Publication Number Publication Date
ATE337001T1 true ATE337001T1 (de) 2006-09-15

Family

ID=30130912

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03765081T ATE337001T1 (de) 2002-07-23 2003-07-22 Antitumorverbindung und ihre therapeutischen verwendungen

Country Status (12)

Country Link
US (2) US20060258731A1 (de)
EP (1) EP1534271B1 (de)
JP (1) JP2005537277A (de)
CN (1) CN1668298A (de)
AT (1) ATE337001T1 (de)
AU (1) AU2003251437A1 (de)
CA (1) CA2493202A1 (de)
DE (1) DE60307856T2 (de)
ES (1) ES2271649T3 (de)
IT (1) ITMI20021620A1 (de)
MX (1) MXPA05000781A (de)
WO (1) WO2004009083A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005068424A1 (en) * 2004-01-20 2005-07-28 Cell Therapeutics Europe S.R.L. Indolinone derivatives as receptor tyrosine kinase ihibitors
WO2006119148A2 (en) * 2005-04-29 2006-11-09 The Ohio State University Research Foundation Keratinocyte growth factor receptor - tyrosine specific inhibitors for the prevention of cancer metastatis
AU2007293280A1 (en) * 2006-09-07 2008-03-13 Astrazeneca Ab Method for evaluating patients for treatment with drugs targeting RET receptor tyrosine kinase
WO2010033941A1 (en) 2008-09-22 2010-03-25 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CN113354649B (zh) 2014-11-16 2024-12-10 阵列生物制药公司 一种新的晶型
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
EP3368039A1 (de) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Punktmutationen bei trk-inhibitor-resistentem krebs und zugehörige verfahren
AU2017246547B2 (en) 2016-04-04 2023-02-23 Loxo Oncology, Inc. Methods of treating pediatric cancers
FI3439662T3 (fi) 2016-04-04 2024-09-04 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3458456B1 (de) 2016-05-18 2020-11-25 Loxo Oncology Inc. Herstellung von (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3740490A1 (de) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituierte pyrazol[3,4-d]pyridin-verbindungen als ret-kinasehemmer
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502072A (en) * 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
US6147106A (en) * 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6130238A (en) * 1997-06-20 2000-10-10 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
JP3663382B2 (ja) * 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤

Also Published As

Publication number Publication date
DE60307856T2 (de) 2007-04-12
WO2004009083A1 (en) 2004-01-29
ITMI20021620A1 (it) 2004-01-23
US20060258731A1 (en) 2006-11-16
ES2271649T3 (es) 2007-04-16
US20090130229A1 (en) 2009-05-21
CA2493202A1 (en) 2004-01-29
EP1534271B1 (de) 2006-08-23
CN1668298A (zh) 2005-09-14
AU2003251437A8 (en) 2004-02-09
MXPA05000781A (es) 2005-09-21
WO2004009083A8 (en) 2005-02-03
EP1534271A1 (de) 2005-06-01
DE60307856D1 (de) 2006-10-05
JP2005537277A (ja) 2005-12-08
AU2003251437A1 (en) 2004-02-09

Similar Documents

Publication Publication Date Title
ATE337001T1 (de) Antitumorverbindung und ihre therapeutischen verwendungen
LTPA2019511I1 (lt) Rapamicino darinys, skirtas plaučių vėžio gydymui
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
DE60309848D1 (de) Purinderivate als kinaseinhibitoren
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
NO20061322L (no) Kinazolinderivater som tyrosin kinase inhibitorer
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
NO20025792L (no) Kinazolinderivater for behandling av tumorer
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
DE60321808D1 (de) Flavon derivate als inhibitoren von cyclin-abhängigen kinasen
CY1106405T1 (el) Παραγωγα κουιναζολινης
EP1675552A4 (de) Zubereitung von 1,6-disubstituierten azabenzimidazolen als kinasehemmer
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
IL166625A0 (en) Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
DE602004011924D1 (de) Chinazoline derivate und ihre anwendung in der krebsbehandlung
MX2007003104A (es) Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a.
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
NO20054494L (no) Peptidvektorer
IS2568B (is) Kínasólínafleiður sem SRC týrósínkínasatálmar
DE60214019D1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
AU2003251595A1 (en) Enhancing treatment of mdr cancer with adenosine a3 antagonists
DE60328516D1 (de) Thia-epothilon derivate zur krebsbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties